Humanistic Burden of (FSGS) Focal Segmental Glomerulosclerosis and IgAN (Immunoglobulin A Nephropathy)

Focal Segmental Glomerulosclerosis Clinical Trial

— HONUS  

Official title:

Humanistic Burden of Rare Kidney Diseases: Understanding the Impact of FSGS and IgAN on Patients and Caregivers Study (HONUS) - A Multi-National, Cross-Sectional Survey Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05200871
• Other study ID #: TVTX-RE021-402
• Status: Completed
• Start date: February 5, 2022
• Est. completion date: October 31, 2023

Study information

• Verified date: February 2024
• Source: Travere Therapeutics, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The aim of this observational study is to assess humanistic burden among adults and children/adolescents with FSGS and IgAN as well as the burden and impact for patient care-partners in six countries (United States [US], United Kingdom [UK], France, Germany, Italy and Spain).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 487
• Est. completion date: October 31, 2023
• Est. primary completion date: October 31, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Adult patients and their adult care-partners: At least 18 years old; Either have a physician-provided diagnosis of FSGS or IgAN (with renal biopsy confirmation of the diagnosis) or being a care-partner for someone with a physician-provided diagnosis of FSGS or IgAN (with renal biopsy confirmation of the diagnosis);
• Able to provide informed consent;
• Located in the United States (US), United Kingdom (UK), Germany, France, Spain or Italy. *Care-partners (paired with adult patients) (defined as the individual [e.g., spouse, parent, sibling, relative, or friend] providing direct disease-related support to the adult patient. **All patient groups including chronic kidney disease (CKD) stage 1-5, with or without dialysis, and with or without kidney transplant will be included.
• Care-partners/parents of children/adolescents: At least 18 years old;
• Being a care-partner of children/adolescents with physician-provided diagnosis of FSGS or IgAN (with renal biopsy or genetic confirmation of the diagnosis);
• Able to provide informed consent; Located in the US, UK, Germany, France, Spain or Italy.
• Care-partners will be defined as family members who provide disease-related support and unpaid care to child/adolescent patients

Exclusion Criteria:

• Patient has FSGS or IgAN secondary to another condition;
• Patient has a history of malignancy other than adequately treated basal cell or squamous cell skin cancer;
• Patient has a co-existing glomerular disease (e.g., membranous nephropathy, lupus nephritis);
• Patient is currently participating in a kidney disease clinical trial, and potentially receiving active treatment as part of the trial.

Related Conditions & MeSH terms

• Focal Segmental Glomerulosclerosis
• Glomerulonephritis, IGA
• Glomerulosclerosis, Focal Segmental
• Immunoglobulin A Nephropathy
• Kidney Diseases

Locations

Country	Name	City	State
Germany	Travere Investigational Site	Villingen-Schwenningen
Spain	Travere Investigational Site	Madrid
United States	Travere Investigational Site	Belmar	New Jersey
United States	Travere Investigational Site	Chapel Hill	North Carolina
United States	Travere Investigational Site	King Of Prussia	Pennsylvania
United States	Travere Investigational Site	San Francisco	California

Sponsors (1)

Lead Sponsor	Collaborator
Travere Therapeutics, Inc.

Countries where clinical trial is conducted

United States,  Germany,  Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Demographics	Adult patients (self-reported) - age, sex, education level, household income, marital status, current work status, race/ethnicity (for patients in the US and in the UK), health insurance (for patients in the US), approximate travel time to receive FSGS/IgAN medical care.; Child/adolescent patients (reported by parent/care-partner) - age, sex, current school status, race/ethnicity (for patients in the US and in the UK), approximate travel time to receive FSGS/IgAN medical care.; Care-partners of adult patients and parents/care-partners of child/adolescent patients - age, sex, education level, household income, marital status, relationship to person with FSGS/IgAN, current work status, race/ethnicity (for patients in the US and UK).	Day 1, day of enrollment
Primary	Disease history.	Adult patients (self-reported) - length of time from onset of symptoms to diagnosis, time since diagnosis, renal biopsy status, comorbidities, CKD (Chronic kidney disease) stage at diagnosis, current CKD stage (including dialysis status), transplant status (including type of transplant and occurrence of rejection or recurrence of disease), current level of proteinuria.; Pediatric/adolescent patients (reported by parent/care-partner) - length of time from onset of symptoms to diagnosis, time since diagnosis, renal biopsy status, comorbidities, CKD stage at diagnosis, current CKD stage (including dialysis status), transplant status (including type of transplant and occurrence of rejection or recurrence of disease), current level of proteinuria.	Day 1, day of enrollment
Primary	Adult patient health-related quality of life.	Measured by Kidney Disease Quality of Life 36-item Short Form Survey (KDQOL-36).	Day 1, day of enrollment
Primary	Pediatric patient health-related quality of life (reported by parent/care-partner).	Measured by Pediatric Quality of Life Inventory (PedsQL) Parent report for teens (ages 13-18) or Parent report for children (ages 8-12).	Day 1, day of enrollment
Primary	Adult patient care-partner and pediatric patient parent/care-partner health-related quality of life.	Measured by 12-Item Short Form Health Survey (SF-12).	Day 1, day of enrollment
Primary	Adult patient, adult patient care-partner and pediatric patient parent/care-partner anxiety.	Measured by General Anxiety Disorder 7 (GAD-7) questionnaire.	Day 1, day of enrollment
Primary	Adult patient, adult patient care-partner and pediatric patient parent/care-partner depression.	Measured by Patient Health Questionnaire 9 (PHQ-9) module.	Day 1, day of enrollment
Primary	Adult patient cognition.	Measured by cognition items of the Massachusetts General Hospital (MGH) Cognitive and Physical Functioning Questionnaire (CPFQ).	Day 1, day of enrollment
Primary	Adult patient symptoms.	Measured by 5-point Likert scale ranking of most burdensome symptoms.	Day 1, day of enrollment
Primary	Pediatric patient symptoms (reported by parent/care-partner).	Measured by 5-point Likert scale ranking of most burdensome symptoms.	Day 1, day of enrollment
Primary	Adult patient, pediatric patient (reported by parent/care-partner), adult patient care-partner and pediatric patient parent/care-partner fear and anxiety for the future.	Measured by 5-point Likert scale fear and anxiety for the future.	Day 1, day of enrollment
Primary	Adult patient productivity impairment.	Measured by Work Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI:SHP).	Day 1, day of enrollment
Primary	Adult patient care-partner and pediatric patient parent/care-partner productivity impairment.	Measured by Work Productivity and Activity Impairment Questionnaire (WPAI) caregiver version.	Day 1, day of enrollment
Primary	Adult patient, adult patient care-partner and pediatric patient parent/care-partner impact of disease.	Measured by and 5-point Likert scale impact on education, career, employment, relationships, personal finances and lifestyle.	Day 1, day of enrollment
Primary	Pediatric/adolescent patient impact of disease (reported by parent/care-partner).	Measured by 5-point Likert scale impact on patient education, career (adolescents), employment (adolescents), relationships and lifestyle.	Day 1, day of enrollment